Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

Balance Sheet

Inspect the capital base behind the business.

Assets

$112.58M

FY 2025 · Annual

-0.6% YoY

Liabilities

$69.24M

FY 2025 · Annual

+91.2% YoY

Equity

$43.35M

FY 2025 · Annual

-43.7% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents55.74M11.36M35.44M45.79M40.79M
Short-term Investments2.62M46.52M50K2.02M14.99M
Net Receivables51.14M297K745K638K1.56M
Inventory00000
Other Current Assets2.05M1.83M2.2M2.55M1.81M
Total Current Assets111.55M60M38.44M51M59.16M
Property, Plant & Equipment (Net)4.87M5.67M4.77M4.4M4.7M
Goodwill10.67M10.67M10.67M10.67M10.67M
Intangible Assets46.82M46.69M46.56M46.54M31.7M
Long-term Investments0581K000
Tax Assets0(581K)005.8M
Other Non-current Assets630K627K577K614K558K
Total Non-current Assets63M63.66M62.58M62.22M53.43M
Total Assets174.55M123.66M101.02M113.22M112.58M
Account Payables3.54M2.39M2.05M1.17M2.34M
Short-term Debt00000
Tax Payables00000
Deferred Revenue18.12M9.42M10.81M7.39M3.33M
Other Current Liabilities2.54M3.83M3.12M3.07M3.74M
Total Current Liabilities47.12M18.98M17.96M13.98M11.37M
Long-term Debt00000
Deferred Tax Liabilities2.08M2.08M273K273K22K
Deferred Revenue (Non-current)32.45M27.73M18.69M14.43M12.38M
Other Non-current Liabilities30K2K06.16M43.91M
Total Non-current Liabilities36.53M32.75M21.04M22.23M57.87M
Total Liabilities83.65M51.73M39M36.21M69.24M
Common Stock434.53M440.28M451.34M484.72M515.47M
Retained Earnings(337.1M)(363.37M)(384.86M)(403.47M)(467M)
Accumulated OCI(5.21M)(3.57M)(3.07M)(2.88M)(3.92M)
Other Stockholders Equity00000
Minority Interest(1.32M)(1.4M)(1.4M)(1.37M)(1.2M)
Total Equity90.9M71.94M62.02M77.01M43.35M
Total Debt2.8M3.9M2.95M2.51M2.42M
Net Debt(52.94M)(7.46M)(32.49M)(43.28M)(38.37M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$35.9M
Short-term Investments$17.4M
Receivables$806.0K
Other Current$2.0M
Total Current Assets$56.2M
PP&E (Net)$4.6M
Goodwill$10.7M
Intangible Assets$31.7M
Long-term Investments$537.0K
Tax Assets$5.8M
Other Non-current$36.0K
Total Non-current Assets$53.4M
Total Assets$109.5M

Analysis

Selected assets total $109.5M for Latest. The largest visible component is Cash & Equivalents at $35.9M, about 32.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
10-QQuarterly reportAug 6, 2026
8-KCurrent reportAug 6, 2026
SC 13GSC 13G filingJul 29, 2026

How much cash does LCTX have?

Lineage Cell Therapeutics, Inc. (LCTX) reported $40.79M in cash and equivalents in fiscal 2025.

How much debt does LCTX carry?

Lineage Cell Therapeutics, Inc. (LCTX) reported $2.42M of total debt, with net debt of -$38.37M.